A Phase 1 Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of ASP2205
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2016
At a glance
- Drugs ASP 2205 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 10 Jun 2016 Status changed from suspended to discontinued because of operational reasons.
- 12 Aug 2015 Planned End Date changed from 1 Aug 2015 to 1 Oct 2015 as per ClinicalTrials.gov record.
- 12 Aug 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Oct 2015 as per ClinicalTrials.gov record.